EU Market Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EU Market Challenges


Pharmaceutical Technology Europe
Volume 23, Issue 10

Complexity of the supply chain throughout the EU

Another challenge faced by client companies is defining their distribution strategy and associated product requirements throughout the distribution process. When distributing products to target markets, the drug product will face varying temperature ranges and transit times, so careful consideration needs to be given to product packaging and distribution configurations.

Variations in country requirements for anti-counterfeiting measures also add to supply chain complexity. For example, the French market requires drug products to have a 2D matrix barcode, incorporating the CIP code and batch and expiry details. Meanwhile in Turkey, each individual saleable unit of drug product must also have a unique serial number, printed both in human readable format and incorporated in a 2D code.

Common pitfalls

For a US company, the MAA submission strategy in Europe can present challenges in itself because of the different filing routes (centralised and decentralised), and the various options and constraints that must be considered depending on the type of product and therapeutic indication.

One of the most common pitfalls of companies moving into the EU from the US is the assumption that complying with FDA requirements will automatically lead to European product approval. This is often not the case. Given the fact that the EU is a far larger market than the US in terms of population, it is worth considering a development programme that meets the combined needs of both regions.

The most cost-efficient approach to drug development is to consider multi-regional or global regulatory requirements as early as possible, thus preventing the need for several development programmes to be initiated to comply with separate regional regulatory requirements. The key to successful global drug development is to seek endorsement and buy-in on the key aspects of pharmaceutical and nonclinical drug development, particularly on the acceptability of clinical trial designs for pivotal studies from the key regulatory authorities. Normally, the main aspects of clinical development packages and pivotal registration trials that need to be aligned are in the areas of clinical endpoints, trial duration, choice of patient population and the selection of active comparators. These deliberations may be met with differing opinions between FDA and EU regulatory authorities, with difficult choices having to be made at the time of protocol finalisation.

Knowing the differences up front can help avoid unpleasant surprises at the product approval stage and, more importantly, can make all the difference to the type of approach that is taken when seeking scientific advice from regulatory authorities.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here